**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum

Dimitrios Boumpas

Mary Crow

Kimme Hyrich

Rik Lories

Iain McInnes

Caroline Ospelt

Thomas Pap

David Pisetsky

Désirée van der Heijde

Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

T: +44 (0)20 3655 5889

E: ard@bmj.com

Twitter: @ARD_BMJ

ISSN: 0003-4967 (print)

ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Review

- 449** Towards molecular-pathology informed clinical trials in childhood arthritis to achieve precision medicine in juvenile idiopathic arthritis
L R Wedderburn, A V Ramanan, A P Croft, K L Hyrich, A D Dick, On behalf of the CLUSTER Consortium

Views on news

- 457** Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management?
N Conrad, I B McInnes, J J V McMurray, N Sattar

Rheumatoid arthritis

- 460** Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial
R CF Hebing, M Lin, M Bulatovic Calasan, I B Muller, S Mahmoud, S Heil, E A Struys, B JF van den Bemt, J WR Twisk, W Lems, M T Nurmohamed, G Jansen, R de Jonge
- 468** Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
L van Ouwkerkerk, M Boers, P Emery, P HP de Jong, R BM Landewé, W Lems, J S Smolen, P Verschueren, T WJ Huizinga, C F Allaart, S A Bergstra

- 476** Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis
A Kerschbaumer, N M Stimakovits, J S Smolen, T Stefanova, E Chwala, D Aletaha

- 483** Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells
A Meyer, R E Sienes, W Nijim, B Zanotti, S Umar, M V Volin, K Van Raemdonck, M Lewis, C Pitzalis, S Arami, M Al-Awqati, H J Chang, P Jetanalin, G Schett, N Sweiss, S Shahrra

Psoriatic arthritis

- 496** Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
L Gossec, S Siebert, P Bergmans, K de Vlam, E Gremese, B Joven-Ibáñez, T V Korotaeva, F Lavie, W Noël, M T Nurmohamed, P P Sfikakis, M Sharaf, E Theander, J S Smolen

- 507** Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin
A Boix-Amorós, M H Badri, J Manasson, R B Blank, R H Haberman, A L Neimann, P V Girija, A Jimenez Hernandez, A Heguy, S B Korolov, R Bonneau, J C Clemente, J U Scher

Spondyloarthritis

- 515** Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
D van der Heijde, A Deodhar, X Baraliakos, M A Brown, H Dobashi, M Dougados, D Elewaut, A M Ellis, C Fleurinck, K Gaffney, L S Gensler, N Haroon, M Magrey, W P Maksymowych, A Marten, U Massow, M Oortgiesen, D Poddubnyy, M Rudwaleit, J Shepherd-Smith, T Tomita, F Van den Bosch, T Vaux, H Xu
- 527** Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis
B Nam, S Jo, S-Y Bang, Y Park, J H Shin, Y-S Park, S Lee, K B Joo, T-H Kim
- 533** Piezo1-mediated mechanotransduction promotes enthesal pathological new bone formation in ankylosing spondylitis
S Chen, Z Li, D Chen, H Cui, J Wang, Z Li, X Li, Z Zheng, Z Zhan, H Liu

Myositis

- 546** Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies
J-B Vulsteke, R Denua, S Dubucquoi, F Coutant, S Sanges, D Goncalves, G Wuyts, P De Haes, D Blockmans, W A Wuyts, K G Claeys, E De Langhe, N Fabien, X Bossuyt

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>




When you have finished with this please recycle it


Vasculitis

- 556** The provisional OMERACT ultrasonography score for giant cell arteritis
C DeJaco, C Ponte, S Monti, D Rozza, C A Scirè, L Terslev, G A W Bruyn, D Boumans, W Hartung, A Hočevar, M Milchert, U M Döhn, C B Mukhtyar, M Aschwanden, P Bosch, D Camellino, S Chrysidis, G Ciancio, M A D'Agostino, T Daikeler, B Dasgupta, E De Miguel, A P Diamantopoulos, C Dufiner, A Agueda, U Fredberg, P Hanova, I T Hansen, E-M Hauge, A Iagnocco, N Inanc, A Juche, R Karalilova, T Kawamoto, K K Keller, H I Keen, T A Kermani, M J Kohler, M Koster, R A Luqmani, P Macchioni, S L Mackie, E Naredo, B D Nielsen, M Ogasawara, C Pineda, V S Schäfer, L Seitz, A Tomelleri, K D Torralba, K S M van der Geest, K J Warrington, W A Schmidt

Epidemiology

- 565** Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases
 *N J Patel, C Cook, K Vanni, X Fu, X Wang, Y Kawano, G Qian, B Hang, S Srivatsan, E P Banasiak, E Kowalski, K Bade, Y Zhang, J A Sparks, Z S Wallace*

Letters

- 575** Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
 *M Dougados, C Charles-Schoeman, Z Szekanecz, J T Giles, S R Ytterberg, D L Bhatt, G G Koch, I Vranic, J Wu, C Wang, K Kwok, S Menon, C A Connell, A Yndestad, J L Rivas, M H Buch*
- 577** Transplacental passage of belimumab during pregnancy and follow-up of a child exposed in utero
H Bitter, D J Warren, N Bolstad, A LI Noraas, M E Ostensen
- 579** Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy
O Landon-Cardinal, H Allard-Chamard, H Chapdelaine, S Doucet, É Rich, J Bourré-Tessier
- 580** Two cases with new onset of ANCA-positive eosinophilic granulomatosis with polyangiitis under treatment with dupilumab: coincidence or causality?
M von Deimling, T C Koehler, B C Frye, E Maerker-Hermann, N Venhoff

Thank you to our reviewers

- 583** Thank you to our reviewers 2022

Electronic pages

- e77** Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'
T Kawada
- e78** Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada
S Piantoni, L Andreoli, E Colombo, M Mendeni, M L Ghirardelli, A Brucato, M Imazio, R Furloni, F Franceschini, P Airó, M Scarsi
- e79** Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'
H Yang, J Xu, L Shi, G Duan, Y Wang
- e80** Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Yang *et al*
S Akiyama, S Hamdeh, D Micic, A Sakuraba
- e81** Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'
C Perricone, E Bartoloni, G Cafaro, R Caporali, R Gerli
- e82** Response to: 'Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'' by Perricone *et al*
B Shah, A Z Reyes, K A Hu, J Teperman, T L Wampler Muskardin, J-C Tardif, M H Pillinger
- e83** Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'
Y H Lee
- e84** Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Lee
S Akiyama, S Hamdeh, D Micic, A Sakuraba
- e85** Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia?
E Duran, L Kiliç, G Durhan, A Ç Inkaya, G S Guven, C Karakaya, O M Ariyurek, O Karadag

- e86** Transient monoarthritis and psoriatic skin lesions following COVID-19
L De Stefano, S Rossi, C Montecucco, S Bugatti
- e87** Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden'
M I Zervou, G N Goulielmos
- e88** Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden' by Zervou *et al*
V Molander, J Asklind
- e89** Correspondence on 'Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis'
A N Georgiadis, E Pelechas, P V Voulgari, A A Drosos
- e90** Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis' by Georgiadis *et al*
S Plein, M H Buch
- e91** Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'
K Reuter, E Rocca
- e92** Response to 'Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis' by Reuter *et al*
C Sharma, S Whittle, P D Haghghi, F Burstein, H I Keen
- e93** Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'
B Zheng
- e94** Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Zheng
S Abtahi, J H M Driessen, A M Burden, P C Souverein, J P van den Bergh, T P van Sijaa, A Boonen, F de Vries
- e95** Correspondence on 'Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study'
J Maquet, M Lafaurie, L Sailler, M Lapeyre-Mestre, G Moulis
- e96** Response to: 'Correspondence on 'Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study' by Maquet *et al*
X-H Chen, J C C Wei, H-Y Mo, H-H Chen
- e97** Response to: 'Correspondence on 'Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study' by Maquet *et al*
X-H Chen, F-X Zhu, H-H Chen, J C-C Wei
- e98** Correspondence on 'Risk of venous thromboembolism in knee, hip and hand osteoarthritis: a general population-based cohort study'
T-K Lin, L-F Pan, G-P Jong
- e99** Response to: 'Correspondence on 'Risk of venous thromboembolism in knee, hip and hand osteoarthritis: a general population-based cohort study' by Lin *et al*
C Zeng, Z Yang, G Lei, Y Zhang
- e100** Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'
J Zou, C-H Lin, Y Wang, Y Shen, J-L Guan
- e101** Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome' by Zou *et al*
J Liu, C Zhao, W Zheng
- e102** Correspondence on 'Non-surgical and surgical treatments for rotator cuff disease: a pragmatic randomised clinical trial with 2-year follow-up after initial rehabilitation'
P Randelli, L A Coletto, A Menon, R Caporali
- e103** Response to: 'Correspondence on 'Non-surgical and surgical treatments for rotator cuff disease: a pragmatic randomised clinical trial with 2-year follow-up after initial rehabilitation' by Randelli *et al*
S Cederqvist, T Flinkkilä, J Ylinen, H Kautiainen, A Tuominen, I Kiviranta, J Paloneva, the Surgery for rotator cuff disease Finland (SURFIN) Investigators